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Summary
Neurofibrillary tangles advance from layer II of the entorhinal cortex (EC-II) toward limbic and
association cortices as Alzheimer disease (AD) evolves. However, the mechanism involved in this
hierarchical pattern of disease progression is unknown. We describe a transgenic mouse model in
which overexpression of human tau P301L is restricted to EC-II. Tau pathology progresses from
EC transgene-expressing neurons to neurons without detectable transgene expression, first to EC
neighboring cells, followed by propagation to neurons downstream in the synaptic circuit such as
the dentate gyrus, CA fields of the hippocampus, and cingulate cortex. Human tau protein spreads
to these regions and co-aggregates with endogenous mouse tau. With age, synaptic degeneration
occurs in the entorhinal target zone and EC neurons are lost. These data suggest that a sequence of
progressive misfolding of tau proteins, circuit-based transfer to new cell populations, and
deafferentation induced degeneration are part of a process of tau-induced neurodegeneration.
© 2012 Elsevier Inc. All rights reserved.
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INTRODUCTION
It has been known for more than 25 years that neurofibrillary tangles have a hierarchical
pattern of accumulation reflecting selective vulnerability of neuronal populations in the
Alzheimer brain, initially affecting the large projection neurons that connect memory related
neural systems (Braak and Braak, 1991; Hyman et al., 1984). The first neurons to be
affected are in layer II of entorhinal cortex (EC), the neurons that give rise to the perforant
pathway, the single major projection linking the cerebral cortex with the hippocampus
(Gomez-Isla et al., 1996; Hyman et al., 1987). Over years, a “march” of lesions appears to
propagate across limbic and association cortices, creating a pattern so consistent as to be
incorporated into criteria for the neuropathological diagnosis of the illness (Hyman and
Trojanowski, 1997). Selective loss of these neurons are believed to contribute to the defects
in memory and higher order cognitive functions in Alzheimer’s disease due to disconnection
and deafferentation of critical neural circuits (Delacourte et al., 1999; Hyman et al., 1990).
Despite recognition of the patterns of anatomical connectivity that link vulnerable neurons,
there is no clear understanding of the mechanism of disease progression. To create a model
of the earliest point in the neurodegenerative cascade of Alzheimer disease, we generated a
new transgenic mouse model in which a mutant form of tau (P301L) linked to tangle
formation in frontotemporal dementia is expressed selectively in a fraction of the neurons of
layer II of entorhinal cortex.
The EC is the predominant cortical input and output network of the hippocampal formation.
These connections are layer specific. The superficial layers provide neuronal projections to
the dentate gyrus in a powerful projection referred to as the perforant pathway (Witter,
2007). In the mouse, layer II of the EC projects directly to the outer two thirds of the
molecular layer of the dentate gyrus, where it connects to dendrites from the granule cells of
the dentate gyrus (Hjorth-Simonsen and Jeune, 1972; Steward, 1976). The major projection
patterns are exquisitely specific, with lateral EC projecting to the outer third of the dentate
molecular layer and the medial EC projecting to the middle third. Smaller projections
provide direct EC-hippocampal and EC cortical connections as well. The superficial layers
of EC receive output from pre- and para-subiculum (Pr-PaS), while the deeper layers –
layers IV, V and VI - receive output from hippocampus (Canto et al., 2008).
With this new transgenic mouse model, we tested the hypothesis that tau pathology would
evolve in the same predictable pattern as the neuropathological development of Alzheimer’s
disease. The results show dramatic “spread” of pathological tau deposits from the neurons
initially expressing human tau mRNA to populations of neurons without detectable
transgene expression, leading to co-aggregation of human tau and endogenous mouse tau in
neurons without detectable levels of human tau mRNA transgene. These data support the
idea that local tau aggregation can be transmitted from neuron to neuron, and may help
explain the anatomical patterns of tangle accumulation in Alzheimer’s disease, supporting
the hypothesis that circuit-based patterns of neurodegeneration play an important role in the
progression of tau pathology.
RESULTS
Restricted transgene expression and age-dependent pathology in EC of rTgTauEC mice
We generated a mouse line that reversibly expresses human variant tau P301L primarily in
layer II of entorhinal cortex, the rTgTauEC mouse (Fig 1A). We took advantage of a mouse
line in which expression of a tet transactivator transgene is under control of the neuropsin
gene promoter (Yasuda and Mayford, 2006). This line was crossed with the Tg(tetO-
tauP301L)4510 line that only expresses human tau carrying the P301L frontotemporal
de Calignon et al. Page 2
Neuron. Author manuscript; available in PMC 2013 February 23.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
dementia mutation in the presence of a tet transactivator (Santacruz et al., 2005). Human tau
expression in bigenic rTgTauEC mice is limited largely to the superficial layers of medial
entorhinal cortex and the closely related pre- and para-subicular cortices (Fig 1B–C).
We assessed the expression of the human tau transgene in this new model by in situ
hybridization. We observed intense expression as early as 3 months of age, in a subset of
neurons in the medial entorhinal cortex (MEC) and pre- and para-subiculum (Pre and Para)
(Fig 1C). The positive neurons in the MEC were detected prominently in layer II, although
rare positive neurons were observed in layer III, especially in the area adjacent to para-
subiculum. A few rare neurons in the granular layer and the hilum of the dentate gyrus (DG)
showed some transgene expression in accord with observations in the parental line (Yasuda
and Mayford, 2006), as well as very rare neurons in CA1, CA3, lateral amygdaloid nucleus,
and superficial cortical areas.
Immunohistochemistry using the 5A6 antibody (courtesy of Dr G.V. Johnson, University of
Rochester), a monoclonal antibody raised against the longest form of recombinant human
tau which recognizes an epitope between amino acids 19 and 46 (Johnson et al., 1997),
confirmed strong expression of tau protein in superficial layers of MEC and para-subiculum
in rTgTauEC mice at 3 months of age, compared to a control brain (Fig 1D). Higher
magnification of the EC and DG area shows transgene expression restricted to the EC,
where there is diffuse axonal staining, and to the axonal terminals in the middle molecular
layer of DG, which receives axons originating in the MEC. This indicates that the human tau
is transported through axons of the MEC to their terminals in the molecular layer of DG (Fig
1D, middle panels). Immunohistochemistry and western blot analysis of Tet-OP301L tau
mice brains revealed no detectable levels of human tau protein expression (S1A and S1B,
respectively) qPCR shows <2% of rTgTauEC levels of htau mRNA in the parental tauP301L
line without transactivator, within the noise of the assay (S1C).
Human tau expression in the MEC results in an age-dependent accumulation of tau
pathology in transgene expressing neurons. The normal axonal distribution of human tau
(Fig 1D) is lost and the protein accumulates in the EC cell bodies. The first sign of tau
pathology was detected at 3 months of age with Alz50 staining, an early indicator of tau
misfolding, in the projection input zone of MEC, corresponding to the middle third of the
molecular layer of the dentate gyrus (Fig 1E, left most panel), while the inner and outer
layers were non-reactive (for higher magnification see S2). This axonal staining preceded
Alz50 staining in the MEC neuronal soma where Alz50-positive tau was first detected at 6
months of age (Fig 1E, second left panel and S1). From 6 months, a slow progression of tau
epitopes in the soma of MEC neurons towards later stages of pathology was observed,
marked by the presence of PHF1 staining, recognizing the late phosphorylation of Ser
396/404 sites, starting at the age of 12 months (Fig 1E, middle panel and S2), Gallyas
staining (Paired Helical Filament-specific silver impregnation) at the age of 18 months (Fig
1E, second right panel and S2), and Thioflavin S staining (β-pleated sheet conformation) at
24 months (Fig 1E, right panel and S2).
Biochemical characterization of mouse brain extracts confirmed age-dependent pathological
changes in tau protein in rTgTauEC mice (Fig 2). Western blot analysis of whole brain
extracts obtained from 12, 18 and 24 month-old rTgTauEC and control mice confirm human
tau protein is expressed in the brain and shows an age-dependent increase in total tau and
human tau (Fig 2A–C). Quantification of tau hyperphosphorylation by western blot analysis
of mouse brain extracts from 12, 18 and 24 month-old rTgTauEC and control mice was
performed by using phospho tau antibodies AT180 (pT231), PHF1 (pS396/404) and CP13
(pS202) and normalized to total tau levels (phosphorylation independent). rTgTauEC mice
present an age-dependent increase in all phospho epitopes (Fig 2D–F). 24 month-old mouse
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brains were subjected to sarkosyl extraction to biochemically confirm the presence of
insoluble tau aggregates. After sarkosyl extraction, a 64 kDa insoluble hyperphosphorylated
tau species was detected by immunoblot in both rTg4510 and rTgTauEC brains, but was
absent in age-matched control brains when analyzed using a total tau antibody (Fig 2G–H).
In the soluble fraction, the 55 kDa species of tau were also present, similar to that seen in
rTg4510 mice (Santacruz et al., 2005).
Human tau protein propagates to synaptically connected brain regions
The data above establish that human tau mRNA expression in the MEC results in human tau
protein expression and age-dependent pathological accumulation in this region as would be
expected. Restricting the transgene expression to the entorhinal cortex also allowed us to
investigate whether pathological tau changes spread through neural circuits as predicted
from pathological studies of AD brain at different stages. The major output of the entorhinal
cortex is a large axonal projection called the perforant pathway that carries input from layers
II and III of EC to the hippocampus, terminating in the middle molecular layer of the DG
(Steward, 1976; Van Hoesen and Pandya, 1975). We hypothesized that tau expression in
MEC would lead to pathological tau accumulation in a hierarchical fashion first in MEC
followed by DG, then the CA2/3 and CA1 regions which are downstream of the DG.
To test the possibility that misfolding of tau could be propagated anterogradely along a
neural network, areas that are synaptically connected to entorhinal cortex were investigated
with histological stains of tau pathology [Fig 3A–C; also see Supplemental Table 1 (ST1)].
We find that neurons in the granular layer of the DG developed tau pathology several
months after lesions appeared in the MEC with Alz50 positive and PHF1 positive soma
appearing in the DG at 18 months, and Gallyas and ThioS positive soma at 24 months (ST1,
Fig S2). CA1 and CA2/3 also develop pathological aggregates by 21 months of age (Fig
3A–C middle and right panels). Western blot analysis was used as an alternative approach to
address if human tau protein and tau hyperphosphorylation are spread to downstream
synaptically connected neurons. The levels of human tau expression and tau phosphorylation
were quantified in the EC and hippocampus dissected from 17 month-old rTgTauEC and
controls. Human tau protein as well as PHF tau could be detected in the EC and
hippocampus of rTgTauEC (Fig S3A–B), confirming the histological data showing human
tau protein present in the hippocampal formation.
This observation of human tau protein and pathology in areas that largely do not express the
human tau transgene indicates that tau pathology spreads from cells expressing the transgene
to downstream neurons. Indeed, combined fluorescence in situ hybridization (FISH) and
immunofluorescent staining for both human tau protein and Alz50, revealed neurons with
human tau and/or misfolded tau that do not have detectable levels of human tau transgene in
the EC (Fig 3D–E), hippocampal fields (Fig S3C–D), and anterior cingulate cortex (CG)
(Fig S3E) showing a dissociation between human tau transgene (htau) expression and
human tau protein accumulation. In the EC, quantification of human tau mRNA and Alz50
positive cells, reveals that only 33.3% of the Alz50 positive neurons in EC express human
tau mRNA at 12 months, indicating spread of misfolded tau to neighboring neurons within
the EC without detectable transgene expression (Fig 3F). By 24 months of age, astonishingly
97% of Alz50-positive neurons (96.4%; stdv +/−6.45; p<0.001) did not have any detectable
human transgene expression, showing that the propagation to neighboring cells increased
with age (Fig 3F) and indicating that transgene expressing neurons may be lost as will be
discussed later.
Alz50-positive aggregates were also found in large numbers of neurons without detectable
transgene expression in the DG, anterior cingulate cortex, CA1 and CA3, all major targets of
the EC (Witter et al., 1988). Importantly, unlike the anterior cingulate cortex, cortical areas
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that showed limited transgene expression outside of the EC, but do not receive direct input
from the entorhinal cortex, did not show any tau aggregation. Moreover, the cerebellum,
which expresses human P301L tau mRNA, did not develop any fibrillar accumulation of
htau in the soma.
These experiments with FISH showing human tau protein and Alz50 positive aggregates in
cells without detectable levels of human tau mRNA confirm the transmission of human tau
from neuron to neuron and rule out the possibility that the transgene promoter was non-
specifically expressing human tau in these hippocampal neurons (i.e. becoming “leaky” in
older animals).
To confirm that the absence of human tau mRNA in the FISH experiments was not due to
limited sensitivity of the technique, we used FISH to label human tau mRNA and
immunofluorescence with HT7 to label human tau protein in sections from 17 month-old
animals. We then used laser capture microscopy to capture three different populations of
cells on an individual cell-by-cell basis for analysis by qPCR: 1) neurons negative for
human tau mRNA and negative for human tau protein; 2) neurons negative for human tau
mRNA and positive for human tau protein; 3) neurons positive for human tau mRNA and
positive for human tau protein (Fig 3E). Total RNA was extracted and qPCR analysis of the
cDNA product was carried out using primers against the transgenic human tau construct.
The qPCR data clearly show that the neurons that were human tau protein positive and were
RNA negative by FISH indeed did not express detectable levels of the tau transgene (Fig
3G), in contrast to robust detection of tau mRNA in neurons positive for tau mRNA by
FISH. Taken together, these data strongly suggest that the human tau protein may be
undergoing neuron-to-neuron transmission.
Human tau seeds mouse tau aggregation
The above experiments strongly suggest the spread of human tau protein from neuron-to-
neuron, which could cause seeding of misfolding and aggregation of tau. It has been shown
previously, in cell culture experiments, that extracellular tau aggregates could be
internalized transmitting tau misfolding from outside to inside of the cell where these
aggregates could seed fibril formation of recombinant tau monomer. Moreover, the same
study showed that tau aggregates were transferred between co-cultured cells. (Frost et al.,
2009). Another recent study reported that brain extracts from NFT-bearing mouse brain
injected in wild-type tau expressing mice induces seeding of tau fibrils in neurons
(Clavaguera et al., 2009).
To determine whether mouse tau is recruited by human tau to aggregate, we performed
immunohistochemistry using an antibody specific for mouse tau that revealed that mouse tau
indeed accumulates in the somatodendritic compartment of MEC neurons of 24 month-old
rTgTauEC mice (Fig 4A). Age-matched control mice have diffuse axonal staining with the
mouse tau antibody and tau knockout mice show no immunoreactivity as expected. Human
AD cases also have no immunoreactivity to mouse tau indicating that the observed
immunoreactivity is not due to human tau becoming reactive to the mouse tau antibody
during pathological changes. Results from double labeling using Alz50 and mouse tau
antibodies shows that Alz50 and mouse tau staining co-localize in neuronal cell bodies of
MEC which is further evidence for mouse tau recruitment into aggregates in the rTgTauEC
mouse model (Fig 4B). Immunoblotting using the mouse tau specific antibody also revealed
that mouse tau increases with age in rTgTauEC mice (Fig 4C), indicating that it may be
accumulating in tangles. In confirmation of this idea, sarkosyl insoluble and soluble
fractions both contain endogenous mouse tau (Fig 4D). The specificity of the mouse tau
antibody was confirmed by Western blot (Fig 4E) which shows mTau reactivity in
rTgTauEC and control mouse brain but not in tau knockout or human AD brain.
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These data suggest that human tau enters neighboring cells that do not have detectable levels
of human tau transgene and transmits a misfolded state which recruits endogenous mouse
tau into the somatodendritic compartment, where it becomes misfolded and contributes to
tau aggregation.
Progressive neurodegeneration and gliosis in rTgTauEC neural circuits
Tau pathology in rTgTauEC mice was first observed as Alz50 staining in the axon terminals
from the perforant pathway arising in EC-II terminating in the middle molecular layer of the
DG (ST1). This has also been observed in AD patients (Hyman et al., 1988), and suggests
that conformationally abnormal tau is axonally transported along the perforant pathway to
pre-synaptic axon terminals, or that the Alz50 epitope is generated first at the axon
terminals. We observed age-dependent degeneration of axon terminals in rTgTauEC mice
(Fig 5A, for higher magnification images see Fig S2 and for pathology progression see
ST1). Alz50 tau staining of misfolded tau in axon terminals increased with age through 12
months (Fig 5A, second left panel). At 18 months, the reactivity in axon terminals decreased
and staining in soma of the molecular layer of the DG became more prominent, indicating
the possibility that EC-II axons began to degenerate and DG granular neurons took up the
misfolded protein (Fig 5A, middle panel). From 21 months of age, the pattern of Alz50
reactivity in the middle molecular layer of the DG changed from a clear layer to irregular
patches in the axon terminal zone (Fig 5A, right panels), similar to a pattern observed in AD
patients (Hyman et al., 1988).
Axonal degeneration was accompanied by gliosis in rTgTauEC brain. rTgTauEC mice
showed evidence of microglial activation (Fig 5B–C) and astrogliosis (Fig 5D–E). At 24
months of age, Alz50-positive patches of axon terminals in the middle molecular layer were
surrounded by activated microglia (Fig 5C) suggesting that axon terminals and their
synapses were degenerating in this area. Double labeling using PHF1, phospho tau antibody,
and GFAP antibody demonstrated reactive astrocytes that were PHF1-positive at 24 months
of age (Fig 5E). The tau transgene is not expressed in glia, and there were no PHF1 positive
astrocytes at earlier ages, indicating human tau is likely released from terminals and taken
up by glia as the axons degenerate.
The irregular patches of Alz50 staining of EC-II axon terminals surrounded by activated
microglia suggest synapses are lost in this region as axons degenerate. Previous studies have
shown that partial deafferentation of granule cells of the dentate gyrus during normal aging
was caused by a loss of axodendritic synapses in the molecular layer, and a loss of
axosomatic synapses (Geinisman, 1979; Geinisman et al., 1977). In Alzheimer’s disease,
early hallmarks include the loss of synapses, and comparison of AD patients to age-matched
control individuals showed that the density of synapses correlated strongly with cognitive
impairment, suggesting that loss of connections is associated with the progression of the
disease (DeKosky and Scheff, 1990; Scheff and Price, 2006; Terry et al., 1991). Therefore,
we assessed two synaptic markers in the perforant pathway terminal zone of rTgTauEC
mice: synapsin-I, a marker of synaptic vesicles, and PSD-95, a postsynaptic marker that has
been reported to decrease early in neurodegeneration (Zhao et al., 2006) (Fig 6A). We used
array tomography to allow high resolution, quantitative measurement of synaptic densities.
We found that both pre- and post-synaptic densities were significantly reduced in the middle
third of the molecular layer at 24 months of age in tau-expressing transgenic mice (Fig 6B).
To estimate neuronal loss, neuronal counts in entorhinal cortex and hippocampal sub-areas
were performed on transgenic and control animals at 21 and 24 months of age (n= 3 to 4
animals per group), using stereological estimations of cresyl violet-labeled neuronal nuclei.
Neurons were identified by their morphology. In rTgTauEC mice, significant neuronal loss
was detected at 24 months of age, in the area of transgene expression, EC-II and
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parasubiculum, compared to the average neuron number in age-matched control brains (Fig
6C). We observed a 42% decrease in neuron density in layer II of entorhinal cortex. We did
not observe significant neuronal loss up to 21 months of age. Quantification by stereological
counts showed that 47% of all neurons in the EC-II were Alz50 positive at 12 months of age
which dropped to approximately 10% at 24 months of age (Fig 6D) as some neurons died.
We hypothesize that the observed age-associated neurodegeneration is due to the age-
dependent toxicity of tau that is pathologically mislocalized to the soma,
hyperphosphorylated, and aggregated, similar to observations in human AD brain. To
formally exclude the possibility that axonal degeneration and neuronal loss at 24 months are
not due to increased transgene expression at later ages, we quantified the percentage of
neurons expressing the human tau transgene. Stereological counts of human tau expressing
neurons labeled with in situ hybridization show that approximately 12% of neurons (12.4%;
sem +/− 1.69) in layer-II of entorhinal cortex expressed the transgene at 3 months of age
(Fig 6E–F). This number was unchanged at 12 months (13.21%; sem +/− 0.86; p=0.366)
and 18 months of age (12.18%; sem +/− 1.96; p=0.481), showing that only a portion of
neurons in the EC-II expressed the human tau transgene. At 24 months of age, only ~4%
(3.71%; sem +/− 0.84) of the neurons expressed the transgene (Fig 1C and 1D) (p<0.005).
The pattern of human tau protein expression also changes as the animals age. There is a
significant reduction in the human tau immunofluorescence staining of the EC at 24 months
and the cell bodies of the DG neurons become immunoreactive for htau, suggesting the
protein is being transmitted (Fig S4).
Together, these data indicate that neurodegeneration begins in this model of early AD with
degeneration of axon terminals followed by loss of synapses and neurons. Further, the cell
loss observed at 24 months exceeds the number of neurons that were expressing the
transgene, suggesting that neurons that develop tau pathology without expressing the
transgene might also be lost.
DISCUSSION
To understand the sequence of events from expression of pathological tau in the entorhinal
cortex to the development of widespread cortical involvement, we recreated an early stage
of AD neurofibrillary pathology in transgenic mice to investigate how, starting in the
entorhinal area, tau pathology leads to neural system dysfunction. We observed two
important consequences of the formation of tangles in the entorhinal cortex: (1) spreading of
the pathology to downstream connected neurons despite regional and cellular restriction of
transgene expression, and (2) evidence favoring very slow synaptic, then axonal, then
somatic degeneration associated with accumulation of misfolded tau.
Recent data suggest that intracellular protein aggregates of tau have the capacity to seed
aggregation of native tau proteins and might propagate their misfolded state in a prion-like
manner. This transmission has first been described to occur inside cells, since incorrectly
folded tau proteins convert to an aggregate-prone state acting as a nucleus that recruits
additional tau monomers (de Calignon et al., 2010; Iliev et al., 2006; Mocanu et al., 2008).
In cell culture experiments (Frost et al., 2009), extracellular tau aggregates could enter cells
and trigger tau fibrillization. In living mouse brain, intracortical injections of tau aggregates
seed tau fibrillization in neurons carrying the human transgene (Clavaguera et al., 2009).
Here, we found that in aged rTgTauEC mice, human tau protein is present in neurons that do
not do not have detectable levels of human tau mRNA, suggesting that transneuronal
propagation of tau occurs. This idea is also supported by our data showing that (1) in EC-II,
the number of transgene-expressing neurons decreases in older age – correlating with
neuronal loss - while (2) the proportion of transgene-negative Alz50-positive neurons
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robustly increases with age, suggesting that the remaining Alz50-positive neurons were
secondarily affected by transneuronal transfer. It has been reported that glial tau pathology
occurs in tauopathies (Ballatore et al., 2007; Chin and Goldman, 1996) and in Alzheimer’s
disease (Nakano et al., 1992; Nishimura et al., 1995; Papasozomenos, 1989a, b) where tau
inclusions can be found in astrocytes and oligodendrocytes. The presence of human tau
protein in GFAP positive astrocytes in rTgTauEC mice suggests that release of tau from
neurons and uptake by glia also takes place in this model.
The specificity of the neurospsin driven transactivator for EC and related structures is
demonstrated by in situ hybridization, qPCR, immunostaining, and western blot analysis of
rTgTauEC mice. Moreover, the parental P301L mice without the transactivator transgene
show levels of human tau protein or mRNA (supplemental figure S1) below detection
thresholds, in accord with a recent observation that the “tau alone” parental line express
<2% of the levels of rTg4510 mice and do not develop any tau pathological alterations with
age (Barten et al. 2011).
Taken together, data presented in this study indicates that, in the rTgTauEC mice, tau was
not only transferred to neighboring cells, but also to synaptically-connected neurons, which
suggested that tau, or a particular species of tau such as hyperphosphorylated tau, misfolded
tau, or a fragment of tau, may have been released at the synapse. In the dentate gyrus, CA
regions, and the cingulate cortex, we found neurons that do not have detectable human tau
mRNA at any of the ages examined, which accumulated tau immunoreactive species
(recognized by multiple antibodies) at advanced ages (21 and 24 months). In parallel to our
study, a recent report described a mouse model of mutant APP expressed predominantly in
the entorhinal cortex which used the same promoter as rTgTauEC mice. Progression of Aβ
deposition to the hippocampus and cingulate cortex was also reported (Harris et al., 2010).
These data suggest that misfolded tau and Aβ share properties that allow propagation
through the extracellular space to disrupt neuronal systems.
Our data support the idea that tau, when accumulated in the terminal zones, induces synaptic
destruction. We cannot distinguish between the possibilities that misfolded axonal tau
induces dying back terminal degeneration, or that release of tau is synaptotoxic. It is not
clear how, or if, misfolded tau gets released and/or taken up by neurons, but the presence of
increased tau CSF levels after injury is consistent with the possibility that injury induces
release (Blennow et al., 1995). In rTgTauEC mice, propagation seems more tightly linked to
the time frame when axons are dying back (21–24 months) than when Alz50-positive tau
can be detected in axon terminals (3 months), but this does not preclude the possibility that
that some tau is released and taken up at earlier ages, or even under normal physiological
circumstances.
Interestingly, by using a new specific mouse tau antibody, we also show evidence that
endogenous mouse tau accumulates in the somatodendritic compartment of EC neurons
where it co-aggregates with human tau. Furthermore, we also report that mouse tau can be
detected in both the sarkosyl soluble and insoluble fractions, suggesting that misfolded
human tau can recruit endogenous mouse tau to aggregate.
If the propagation of AD tangle pathology from Braak stage I to VI entails, to some extent,
the type of neuronal system propagation events described here, several critical questions
remain. 1) Why are some neuronal populations protected from developing tangles despite
being anatomically strongly connected to neuronal populations that do develop tangles? 2)
Does tau need to emerge into the extracellular space where it is potentially available to
therapies such as immunotherapy or might it be released from the cytoplasm, yet remain
sequestered within membrane bound compartments such as exosomes? 3) Which species of
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tau are responsible for transferring the aggregated state to non-expressing cells? Is the tau
that is capable of initiating misfolded aggregates in downstream cells an aggregated form or
a consequence of a unique post-translational modification such as phosphorylation,
acetylation, glycosylation, or truncation? Understanding these issues may help inform
therapeutic approaches that have promise to slow the progression of AD.
EXPERIMENTAL PROCEDURES
Animals
We generated the line of transgenic animals (called rTgTauEC – for reversible tau restricted
to entorhinal cortex) by crossing FVB-Tg(tetO-TauP301L)4510 mice (Santacruz et al., 2005)
with a transgenic mouse line on a C57BL/6 genetic background expressing tet transactivator
under the control of the neuropsin promoter ( that was developed at the Scripps Research
Institute (Yasuda and Mayford, 2006). Only F1 offspring were used as experimental animals
ensuring a uniform 50:50 mix of FVB and C57BL/6 genetic background. The human Tau
gene with the P301L mutation in rTg4510 mice is downstream of a tetracycline-operon
responsive element and requires the presence of the tet transactivator (Gossen and Bujard,
1992). Since the tet transactivator is downstream of the promoter of neuropsin, human
tauP301L expression is restricted to layer II of entorhinal cortex. Mice with both the activator
and responder transgenes are abbreviated rTgTauEC. Age matched littermates expressing
only the activator transgene and the responder transgene were used as controls. Mice were
screened by PCR using the primer pairs 5′ ACCTGGACATGCTGTGATAA 3′ and 5′
TGCTCCCATTCATCAGTTCC 3′ for activator transgenes, and 5′-TGA ACC AGG ATG
GCT GAG CC-3′ and 5′-TTG TCA TCG CTT CCA GTC CCC G-3′ for responder
transgenes. Each of the 8 age groups studied (3, 6, 9, 12, 15, 18, 21, 24 months) contained
transgenic and control animals. A total of 183 animals were used for this study, including 97
transgenic and 86 control animals. All animal experiments were carried out under national
guidelines (United States National Institutes of Health) and approved by Massachusetts
General Hospital and McLaughlin Institute Institutional Animal Care and Use Committees.
Stereology and Immunocytochemistry
The animals were euthanized by CO2 asphyxiation and the brains harvested, fixed in 4%
paraformaldehyde containing 15% glycerol cryoprotectant for 2–3 days, then either
sectioned or stored at 4°C in a 20% sucrose solution. The brains were frozen and serial
horizontal sections 40 μm thick were cut on a freezing sliding microtome. Groups of every
ten sections were used to characterize each brain.
Unbiased stereologic counting method was used to determine the number of neurons per
region of the brain (Hyman et al., 1998). The optical dissector technique was used in a
similar fashion to previously described work in transgenic mice (Irizarry et al., 1997). The
image analysis system NewCAST (stereology module for VIS; Visiopharm Integration
System ver. 2.12.3.0; Denmark), mounted on an upright microscope Olympus BX51
(Olympus, Denmark) with an integrated motorized stage (PRIOR-Proscan II, Prior
Scientific, Rockland, MA) was used to outline regions, sample and count.
Counting frames of size 21.8 μm x 21.8 μm, and step length from 100 μm to 200 μm were
selected to count >200 neurons per animal. The different brain regions were defined using
the “Franklin K, Paxinos G. The Mouse Brain in Stereotaxic Coordinates, 3rd ed. San
Diego: Academic Press, 2007” atlas. The differentiation between the medial and the lateral
areas of the entorhinal cortex was made using the atlas mentioned above and the mapping of
van Groen (van Groen, 2001).
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Standard immunofluorescence techniques were used to label Tau epitopes. Endogenous
peroxidase activity was quenched for 30 min in H2O2. After blocking in 5% milk for 1 hour,
the appropriate primary antibody was applied, and sections were incubated overnight at 4°C.
Sections were subsequently washed in TBS to remove excess primary antibody. Sections
were incubated in the appropriate secondary antibody for 1 h at room temperature. After
serial washes in TBS, slides were developed with diaminobenzidine substrate by using the
avidin-biotin horseradish peroxidase system (Vector Laboratories). Fluorescent CY3-labeled
secondary antibody (Invitrogen) was used to reveal 5A6.
The antibodies with 5A6 (by G.V. Johnson, 1997; 1:1,000), HT7 (Thermo Scientific;
1:1,000), and TauY9 (Enzo Life Sciences; 1:1,000) were used to specifically detect human
tau; the conformation-specific Alz50 antibody (courtesy Peter Davies, Albert Einstein
College of Medicine; 1:50) and phospho-396/404 tau PHF1 (courtesy Peter Davies; 1:500)
antibodies were used to detect pre-tangle stages. Fluorescent CY3-labeled secondary
antibody (Invitrogen) was used to reveal HT7, and non-fluorescent biotinylated secondary
antibodies revealed by DAB were used to detect Alz50 and PHF1. The antibody Iba1
(Wako, 1:1,000) was used to reveal microglia. Activated astrocytes were labeled using the
GFAP antibody (Sigma, 1:1,000).
The mouse tau specific antibody (mTau) is a polyclonal rabbit antibody which was
generated by Dr. Naruhiko Sahara. Briefly, mTau was raised against a mouse tau epitope,
which is absent in the human tau sequence and it corresponds to amino acid residues 118–
131 (SKDRTGNDEKKAKG). The antibody was characterized by western blot analysis and
immunohistochemistry for sensitivity and specificity and did not recognize any unspecific
proteins in tau knockout mice or in human brain. Tau knock-out (KO) mice, which have a
targeted disruption of exon 1 of tau (Tucker et al., 2001), were used for the characterization
of the mTau antibody. TauKO mice were bred with C57Bl/6 mice to produce TauKO
heterozygote mice also used in the antibody characterization.
Gallyas silver staining was performed on brain sections according to previous description
(Gallyas, 1971). Thioflavin-S staining was performed by leaving the mounted sections for 8
minutes in a solution of 0.05% Thioflavin S in 50% ethanol, rinsed in ethanol 100%, then
water (Sun et al., 2002).
Images for figures were collected on an upright Olympus BX51 microscope (Olympus
America, Center Valley, PA).
In situ hybridization and riboprobe generation
Colorimetric in situ hybridization and riboprobe generation were performed as previously
described (Schaeren-Wiemers and Gerfin-Moser, 1993). Fluorescent in situ hybridization
(FISH) with Alz50 co-immunohistochemistry was performed as previously described (Price
et al., 2002). Riboprobe templates were generated by RT-PCR from mouse and human brain
tissue and correspond to the 3′UTRs of mouse Mapt (NM_001038609.1; nucleotides
1606.2588) and human Mapt (NM_016835; nucleotides 2773..3602).
Laser capture microdissection and qPCR analysis following FISH and
immunofluorescence
Cryosections (10 μm) of snap frozen brains from 24 month-old rTgTauEC mice were
collected on microscopy slides (Gold Seal Rite-On Micro Slides, Portsmouth, NH).
Following FISH, each tissue section was fixed in 70% ethanol (EtOH) for 40 seconds, rinsed
with RNAse free PBS, incubated with the human tau specific HT7 antibody in PBS for
10min, rinsed with PBS, incubated with Alexa 488 goat anti-mouse IgG (InVitrogen) in PBS
for 10min, rinsed with PBS followed by dehydration in increasingly concentrated ethanol
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70–100% into xylene. Different populations of cells were captured after FISH and
immunofluorescence that can be divided in three groups: 1) tau mRNA negative and human
protein negative neurons; 2) mRNA negative and human tau protein positive neurons; 3)
transgene mRNA positive and human tau protein positive neurons. Approximately 500 cells
from EC-II and the DG were captured per group onto separate polyethylene collecting caps
(Macro Cap, Arcturus, MDS Analytical Technologies, Sunnyvale, CA). Total RNA was
extracted using the Arcturus PicoPure RNA isolation kit per manufacturer’s instructions.
Samples were eluted in 14 μl. RNA samples were assayed for quality with an Agilent 6000
Bioanalyzer and a Nanodrop spectrophotometer. Reverse transcription was carried out on all
RNA samples (Superscript II, Invitrogen) and random hexamers. Quantitative PCR (qPCR)
analysis (on Bio-Rad iCycler ) of the cDNA product was carried out using primers against
the transgenic human tau construct (5′-CCC AAT CAC TGC CTA TAC CC-3′ and 5′-CCA
CGA GAA TGC GAA GGA-3′), mouse tau exon 7 (5′-AGC CCT AAG ACT CCT CCA-3′
and 5′-TGC TGT AGC CGC TTC GTT CT-3′) and GAPDH (5′-TGG TGA AGC AGG
CAT CTG AG-3′ and 5′-TGC TGT TGA AGT CGC AGG AG-3′). Triplicates of cDNA
samples were added to a 25 μl reaction containing 12.5 μl SYBR green Mastermix (Applied
Biotechnology). For the standard curve, we subcloned cDNA amplicons, generated using the
qPCR primers in the pcDNA 3.1 vector system (Invitrogen) according to the manufacturer’s
instructions. After verifying the respective specificities of the cDNA clones by sequencing,
these were used to generate individual standard curves, thus allowing for calculation of
molarity and number of mRNA molecules in the samples. Finally, the respective tau mRNA
levels were normalized to murine tau mRNA levels.
Western Blot Analysis
Animals were sacrificed by decapitation, the brains were extracted and either the brain or
hippocampi and entorhinal cortex were dissected. Tissue was homogenized in RIPA buffer
(Sigma) supplemented with a cocktail of protease and phosphatase inhibitors (Roche).
Samples were homogenized using a Polytron and stored at −80°C. T he materials for SDS-
PAGE were obtained from Invitrogen (NuPAGE system). Protein lysates were boiled in
sample buffer consisting of LDS Sample Buffer and reducing Agent, resolved on 4%–12%
Bis-Tris polyacrylamide precast gels in a MOPS-SDS running buffer containing antioxidant.
For most analyses, 30 μg/lane were loaded, unless indicated otherwise. Gels were
transferred onto Nitrocellulose Membranes Protran (Whatman) in transfer buffer containing
20% methanol. Blots were blocked in Odyssey blocking buffer (Li-Cor biosciences),
followed by incubation with primary antibodies [β-actin (Sigma; 1:10,000; Total Tau (Dako;
1:10,000), HT7 (1:5,000), TauY9 (1;1,1000), mTau (Naruhiko Sahara; 1:5,000), AT180
(pT231; 1:1,000; Thermo Scientific), PHF1 (Peter Davies; 1:5,000) CP13 (Peter Davies,
1:1,000) and DA9 (Peter Davies; 1: 10,000)] and detected with anti-mouse or -rabbit IgG
conjugated to IRDye 680 or 800 (1:10,000, Li-Cor biosciences). Densitometric and MW
analyses were performed using ImageJ software (NIH). Band density values were
normalized to β-actin or total tau levels when tau phosphorylation levels were analyzed.
Mean band densities for samples from rTgTauEC mice were normalized to corresponding
samples from control mice.
Sarkosyl insolubility assay
Purification of sarkosyl-insoluble tau was performed as previously described (Hasegawa et
al., 2007) with slight modifications. Briefly, whole frozen brains of 24 and 18 month-old
rTgTauEC (n=3), control (n=3), and 18 month-old rTg4510 (n=1) mice were homogenized
by polytron in 10 volumes of buffer H (10mMTris–HCl, pH 7.5 containing 0.8M NaCl, 1
mM EGTA, and 1mM DTT) and spun at 100,000xg for 30 min at 4°C. Another 2ml of
buffer H was added to the pellet and the samples were homogenized again by polytron,
incubated in 1% Triton-X100 at 37°C for 30 min. Following the incubation, the samples
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were spun at 100,000xg for 30 min at 4°C, the pellet was homogenized by polytron on 1ml
of buffer H then incubated in 1% sarkosyl at 37°C for 30 min and spun 100,000xg for 30
min at 4°C. The supernatant was collected (sarkosyl-soluble fraction). Detergent-insoluble
pellets were extracted in 100 μl of Urea buffer (8M Urea, 50mM Tris–HCl pH 7.5),
sonicated and spun at 100,000xg for 30 min at 4°C. The supernatant was collected (sarkosyl-
insoluble fraction). The protein concentration of extracts was determined by BCA assay
(Thermo Scientific) and either 25 μg/lane (rTgTauEC) or 5 μg/lane (rTg4510) were loaded
were loaded. Sarkosyl-insoluble and soluble fractions were run on SDS-PAGE gels (4–
20%), transferred to nitrocellulose membranes and probed with total tau DA9 (epitope: aa
112 to 129) mouse monoclonal antibody (courtesy Peter Davies, Albert Einstein College of
Medicine; 1:1,000). The DA9 antibody recognizes both human and mouse tau proteins and
was generated against human tau preparations (Tremblay et al., 2011).
Array tomography
Tissue blocks from the dentate gyrus of 21 month old and 24 month old rTgTauEC (n=3 at
21 months, 3 at 24 months old) mice and littermate controls (n=5 at 21 months, 3 at 24
months old) were prepared for array tomography as described previously (Koffie et al.,
2009; Micheva and Smith, 2007). Briefly, mice were sacrificed using carbon dioxide, brains
removed, and small blocks containing DG were dissected, fixed in 4% paraformaldehyde
with 2.5% sucrose in PBS for 2 hours, dehydrated, and embedded in LR White resin
(Electron Microscopy Sciences, Hatfield, PA). Ribbons of ultrathin sections (70nm) were
collected on slides and stained with antibodies to synapsin I (rabbit polyclonal Ab1543
Millipore, Billerica, MA) PSD95 (goat polyclonal Abcam Ab12093, Cambridge, MA) and
secondary donkey anti rabbit Cy3 and donkey anti goat Cy5 (Jackson ImmunoResearch,
West Grove, PA) counterstained with a fluorescent Nissl counterstain (NeuroTrace blue,
N21479, Invitrogen, Carlsbad, CA). Images of the same area of the middle molecular layer
of the dentate gyrus were obtained on 7–11 serial sections in 2 different sample sites per
animal using a Leica TCS SL confocal (Leica Microsystems Bannockburn, IL). Images were
made into stacks and aligned using ImageJ (NIH free software). 3–6 crop boxes were chosen
in each stack in a region free of nuclei. Each crop was analyzed using the watershed
program (generously provided by B Busse and Stephen Smith) to count puncta that are
present in more than one consecutive image in the stack to remove noise.
Data were analyzed using JMP (SAS institute, Cary, NC). Normality of the data was tested
using a Shapiro-Wilks test. One Way ANOVA was used to compare means of the different
genotypes. Data are presented as mean ± s.e.m. from the mean.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Tau pathology propagates to surrounding mRNA-negative cells (neurons and
astrocytes)
• Human tau protein spreads misfolding to downstream synaptically connected
areas
• Human tau seeds misfolding of mouse tau
• mRNA-negative DG neurons developed tangles
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Figure 1. Medial entorhinal cortex-restricted expression of human P301L mutated tau causes
progressive tauopathy in EC neurons
The rTgTauEC transgenic mice express human tauP301L under a tetracycline responsive
promoter (tetO) and the tetracycline transactivator (tTA) under the neuropsin promoter (A).
A low magnification view of a medial horizontal section of rTgTauEC mouse brain stained
with DAPI (B) and fluorescent in situ hybridization (FISH) showing human tau mRNA (C)
demonstrates the restriction of expression of human tauP301L to layer II of the medial
entorhinal cortex (MEC) and the pre- and para-subiculum (Pre, Para). (A–C) The EC and
MEC are outlined with a red dotted line. Note the lack of expression in the lateral entorhinal
cortex (LEC), the subiculum (Sub), and the hippocampus including the dentate gyrus (DG),
CA3 and CA1. There was no transgene expression in age matched controls (right panel, C).
Scale bar, 1mm (B,C). (B) Higher magnification insets show the white outline EC area,
Scale, 100μm. Immunohistolabeling with phosphorylation-independent tau antibody 5A6
shows that tau protein is intensely expressed from 3 months of age compared to an age-
matched control brain (D, Scale bar, 1mm left, 200μm in higher magnification insets).
Human tau expressing neurons in the MEC develop progressive tau pathology (E) beginning
at 3 months of age with Alz50 positive tau misfolding in the axon terminal zone (molecular
layer of the DG, left panel, scale bar 200 μm). By 6 months of age, MEC neurons have
Alz50 positive tau staining in their soma, and the soma in this region increasingly
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accumulates pathological forms of tau with age, shown here by markers of later tau
pathology including PHF1 (tau phosphorylated at Ser396 and Ser404) starting from 12
months, Gallyas silver stain positive neurons from 18 months, and Thioflavin S positive
neurofibrillary tangles by 24 months of age. Scale bar 50 μm for all soma images.
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Figure 2. Biochemical characterization of tau pathology reveals age dependent increase in tau
hyperphosphorylation and presence of sarkosyl insoluble tau in rTgTauEC
(A) Representative immunoblots from western blots analysis of mouse brain extracts from
12, 18 and 24 month-old rTgTauEC and control mice. Antibodies specific to phospho tau
[AT180 (pT231), PHF1 (pS396/404) and CP13 (pS202)], total tau, and human tau (htau)
were used. Quantification of immunoblots shows that rTgTauEC mice present an age-
dependent increase in total tau (B), human tau (results are expressed as percent of total tau
expression at 24 months, the highest expression point defined as 100%) (C), and phospho
epitopes (D–F) (n=4 mice per group). A series of ultracentrifugation and extraction steps
were used to obtain sarkosyl-insoluble fractions of tau from whole brain of 24 month-old
rTgTauEC, control (25 μg of protein loaded), and 18 month-old rTg4510 mice (5 μg of
protein loaded) (positive control). Sarkosyl soluble (S) and insoluble fractions (I) were
immunoblotted with total tau antibody (phosphorylation independent, Dako). Representative
western blots of sarkosyl fractions are shown. (G). Control mice did not show sarkosyl
insoluble tau. In contrast, immunoblotting of fractions from rTgTauEC mice revealed
sarkosyl insoluble complexes of tau, of the same type as found in the brains of rTg4510
mice. A 64 kDa insoluble hyperphosphorylated tau species was detected by immunoblot in
both rTg4510 and rTgTauEC brains, but were absent in age-matched control brains when
analyzed using total tau antibody. In the soluble fraction, the 55 kDa species of tau were also
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present, similar to the species present in rTg4510 mice. (H) Shows quantification of samples
of sarkosyl fractions (n=3 mice per group). Results are expressed as mean ± s.e.m. *P<0.05;
**P<0.01; ***P<0.001.
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Figure 3. Tau propagates through neural circuits to mRNA-negative cells
Several markers of pathological tau accumulation: Alz50 (A), PHF1 (B), and Gallyas silver
staining (C), appear in brain regions synaptically connected to EC via the perforant pathway
including DG, CA1, and CA2/3 (Scale bar 50 μm). FISH for tau mRNA (green), coupled
with immunolabeling (red) with Alz50 (D) or HT7 (E) shows absence of mRNA in some
cells containing the tau protein (arrows). Scale bar, 20 μm. Co-localization of tau mRNA
and Alz50-positive aggregates was assessed by stereology at different ages, and compared to
the total population of neurons carrying Alz50 aggregates. At 12 months of age, a third of
the neurons affected by the tau pathology were expressing the transgene, while only ~3%
were positive for MAPT gene at 24 months of age (F). FISH for MAPT mRNA (green),
coupled with immunolabeling using HT7 (red) in the same EC sections from 17 month-old
animals (E) was used to laser capture three different population of cells (G): 1) tau mRNA
negative and human protein negative neurons; 2) mRNA negative and human tau protein
positive neurons; 3) transgene mRNA positive and human tau protein positive neurons. (G)
Total RNA was extracted and qPCR analysis of the cDNA product was carried out using
primers against the transgenic human tau construct showing that the neurons which were
human tau protein positive and were RNA negative by FISH did not express the tau
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transgene, confirming tau transmission to neurons that do not express the human tau
transgene. Results are expressed as mean ± s.e.m. *P<0.001.
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Figure 4. Human tau protein seeds endogenous mouse tau pathology
Immunohistochemistry using a mouse specific tau antibody (mTau) shows normal axonal
distribution of mouse tau in the control mice and somatodendritic accumulation of mouse
tau in rTgTauEC mice in the EC at 18 months of age (A). The mTau antibody showed no
staining in tau knockout mice or human AD brain. Scale bars, 100 μm. Double labeling
using Alz50 and mouse tau antibodies shows that Alz50 and mouse tau staining co-localize
in neuronal cell bodies (B, Scale bar, 20 μm). (C) Whole brain extracts from rTgTauEC
mice at different ages show an age-dependent increase in mouse tau. Representative blots
are shown on top and quantification on the bottom (n=4 mice per group). (D) Sarkosyl
insoluble and soluble fractions from whole brain of 18 and 24 month-old rTgTauEC probed
using the mouse tau specific antibody mTau revealed that sarkosyl insoluble and soluble
fractions both contain endogenous mouse tau (E). Immunoblotting of brain extracts using
the mouse tau specific antibody confirmed its specificity since it does not recognize protein
in tau knockout brain or human AD brain. Results are expressed as mean ± s.e.m. *P<0.05.
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Figure 5. Axon terminals degenerate progressively in the terminal zone of EC-II axons
The terminal zone of axonal projections from the layer II MEC neurons with the granular
layer (gl) and the middle- molecular layers (mml) which express the human tau transgene
developed early accumulation of misfolded tau (Alz50 staining, A) which intensified up to
12 months of age. At 18 months, the terminal staining with Alz50 became fainter with DG
neurons in the granular cell layer becoming more prominently stained. At 21 and 24 months,
Alz50 staining in the terminal zone was patchy indicating degeneration of Alz50 containing
axons (Scale bar 100 μm, A). Concomitant with this axonal degeneration, we observe
increased microglial activation (Iba1 staining) at 24 months of age in rTgTauEC mice in the
molecular layer of the dentate gyrus (B) Double Immunohistolabeling with Alz50 and Iba1
shows that the patches of Alz50 staining of the axon terminals in the middle molecular layer
of dentate gyrus are surrounded by activated microglia (C, shown in higher magnification in
the inset. Scale bars, 50 μm left panel), and 20 μm right panel). GFAP labeled astrocytes are
more prevalent in rTgTauEC brain than controls (D, Scale bar, 50 μm). Co-localization of
GFAP and PHF1-positive aggregates indicate uptake of tau by astrocytes (E, Scale bar, 20
μm).
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Figure 6. Synaptic loss in the target zone of the perforant pathway and loss of EC-II neurons in
rTgTauEC mice
Array tomography using synapsin I (green) and PSD95 (red) to label pre and postsynaptic
structures in the middle molecular layer of the DG (A, scale bar 2 μm) shows pre and post-
synaptic loss at 24 months of age in the middle molecular layer of the dentate gyrus (B),
indicating loss of synapses between EC-II neurons and DG neurons. (C) Numbers of
neurons were estimated by stereology for different areas of the brain (EC 3–6, layers III to
VI of entorhinal cortex; EC 2, layer II; DG, granular layer of dentate gyrus; CA2-3; CA1;
presubiculum; parasubiculum). Significant neuronal loss was detected at 24 months of age in
the layer II of entorhinal cortex and parasubiculum, compared to age-matched control brain.
(D) Similar stereological quantification showed that 47% of neurons in the EC were Alz50
positive at 12 months of age and approximately 10% at 24 months of age. (E and F) Levels
of transgene expression: loss of neurons could not be explained by an increase in transgene
expression with age since the level of transgene expression assessed by stereological counts
of tau mRNA positive neurons labeled with in situ hybridization showed that the level of
transgene expression in MEC did not change from 3 to 18 months of age and significantly
decreased at 24 months (E, F Scale, 100μm). Results are expressed as mean ± s.e.m.
*P<0.05.
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